How to decide whether to buy, hold, or sell a fallen ASX share

A falling share price can create one of the hardest decisions in investing.

Should you buy more, keep holding, or cut your losses?

The answer depends on what has changed. A share price fall can create a genuine opportunity when the market has become too pessimistic about a strong business.

It can also be a warning sign when the company keeps missing expectations, burning cash, or relying on investors to fund the story.

Here is a simple way to think through it.

Start with the reason for the fall

The first step is to understand why the share price has declined.

Some falls are driven by market-wide pressure. Rising interest rates, recession fears, sector selloffs, and valuation resets can drag down good companies along with weaker ones.

Other falls are more company-specific. Earnings downgrades, weak sales, management changes, balance sheet stress, or repeated execution problems can point to deeper issues.

This distinction is important. A quality company caught in a broad selloff can become more attractive as the price falls. A company with a deteriorating business model may become riskier with every decline.

Check whether the business still has substance

The next question is whether the company still has something valuable underneath the falling share price.

This could be a strong brand, essential product, loyal customer base, high switching costs, valuable infrastructure, recurring revenue, or exposure to a market with long-term demand.

ResMed Inc (ASX: RMD) is a useful example of a fallen share that could still justify a positive view.

Its share price has been under pressure, but the company remains a global leader in sleep apnoea treatment and connected respiratory care. The long-term need for better diagnosis, treatment, masks, devices, and patient support has not disappeared. That gives investors a real business to assess, rather than simply a share price chart to react to.

When a company still has scale, earnings power, and a large market opportunity, buying on weakness can make sense for patient investors.

Look at the numbers, not just the story

Shares often come with persuasive narratives.

Management may talk about technology, innovation, disruption, and large future markets. Those claims become far more useful when they are supported by revenue, cash flow, customer adoption, and improving economics.

This is where Brainchip Holdings Ltd (ASX: BRN) looks very different.

Its shares are down 16% over the past 12 months and 70% over the past five years. It has consistently been making new 52-week lows since 2022, while the company continues to talk up its technology but has delivered next to no revenue and significant dilution from share issues.

That is a warning for investors. A share can keep looking cheaper as the price falls, while the underlying business fails to build the revenue base needed to support the valuation.

Decide what would change your mind

Investors should know what they need to see before buying more or continuing to hold.

For a high-quality ASX share, that might be evidence that margins are stabilising, demand remains strong, new products are gaining traction, or management is executing well.

For a speculative company, the bar should be higher. Investors may want to see meaningful revenue, commercial contracts, less reliance on capital raisings, and proof that customers are willing to pay for the technology.

Buy, hold, or sell?

Buying more can make sense when the business remains strong, the balance sheet is sound, and the market appears too focused on short-term concerns.

Holding can be sensible when the company is still attractive but there is not enough evidence yet to increase exposure.

Selling becomes easier to justify when the company’s problems are worsening, the story is not translating into financial progress, or shareholders are being diluted while waiting for promised growth.

The best decision is rarely based on the share price fall alone. It likely comes from comparing today’s price with the quality of the business, the strength of the balance sheet, the evidence in the numbers, and the probability that the company can create value over the years ahead.

The post How to decide whether to buy, hold, or sell a fallen ASX share appeared first on The Motley Fool Australia.

More reading

• Should I buy CSL and ResMed shares right now?
• 2 ASX shares tipped to grow 50% or more in the next 12 months
• 8 ASX shares with 30% to 220% upside ahead: Experts
• Healthcare shares led the ASX 200 last week. Is a sector comeback underway?
• How to build a $1 million ASX share portfolio for retirement

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.